United States: China's Legislature Passes The New Drug Administration Law

Last Updated: September 2 2019
Article by Katherine Wang

After almost two years of extensive review and deliberation, the Chinese legislature finally passed the new Drug Administration Law ("DAL") on August 26, 2019, which will go into effect on December 1, 2019.

Noteworthy Differences from the Most Recent Draft

The final version of the DAL remains largely consistent with the second draft issued in April 20191 though there are a few noteworthy differences. First, the final version of the new DAL takes a more lenient approach to online sale of prescription drugs. Except for certain high-risk pharmaceutical products,2 online sale of prescription drugs is not entirely prohibited, but it must satisfy separate regulations to be issued by the National Medical Products Administration ("NMPA"). The new DAL also revises the definition of counterfeit drugs. Counterfeit drugs typically refer to drugs that are contaminated, contain no or incorrect active ingredients, or have the right active ingredients but at the wrong dose. The current DAL treats unapproved drugs as counterfeit drugs, which deviates from the common understanding. The new DAL focuses the definition on active ingredients and claims, rather than regulatory approvals. While importing and selling unapproved drugs in large quantities is still illegal, these acts would be not deemed equivalent to importing and selling counterfeit drugs, which is a criminal offense. Last but not least, the new DAL requires foreign pharmaceutical companies to appoint a legal agent in China. The legal agent will need to assume the same regulatory obligations and liability as the foreign marketing authorization holder.

Rewarding Innovation and Deterring Misconduct

The new DAL codifies many of the major reform initiatives implemented by the Chinese government since 2015. The Marketing Authorization Holder (MAH) system, compassionate use, conditional approvals, and priority review/approval for pediatric and orphan drugs are representative examples. The new DAL also signals a clear shift from stringent pre-approval supervision to active post-approval enforcement. For example, pharmaceutical manufacturers and distributors (including retailers) must be certified every five years for GMP and GSP compliance under the current DAL. The new DAL replaces the static certification system with a dynamic inspection system. Pharmaceutical manufacturers and distributors need to be prepared for fly-in inspections at an increased frequency. The NMPA will expand its inspection force to more effectively supervise the operations of pharmaceutical companies, both at home and abroad, as well as their vendors and suppliers. Failure to comply with the statutory obligations will result in more severe penalties, both in the scale of fines and in the forms of sanctions. For example, falsification of regulatory approvals and regulatory dossiers will result in increased fines (from up to three to 15 times the illegal proceeds). The legal representative and main responsible persons of the company will face new sanctions, including 10 years of debarment and detention by the police.

Unresolved Questions

The new DAL does not provide sufficient clarity to a few critical issues. First, patent linkage and regulatory data protection have been an area of concern for R&D-based pharmaceutical companies. Although both the State Council and the NMPA have promoted these mechanisms in previous policies, they are not included in the new DAL. It is unclear whether the Chinese government will continue to advance these mechanisms and include procedural details in the PRC Patent Law as well as the Implementing Regulations of the DAL.

Another interesting question is whether the MAH system will provide more flexibility in structuring cross-border transactions. Under the current DAL, imported and domestic drugs are subject to two different regulatory pathways. Historically, regulatory approvals for imported drugs would be issued to the foreign marketing authorization holders, yet regulatory approvals for domestic drugs would be issued to the actual manufacturers in China. Under the new DAL, the MAH system applies equally to imported and domestic drugs. Subject to the NMPA's approval, marketing authorizations can be transferred from one company to another without changing contract manufacturers. These changes could potentially result in a convergence of the bifurcated pathways and enable Chinese MAHs to work with overseas CMOs. Likewise, foreign MAHs may also choose to work with CMOs in China and restructure their supply chains. If such theses become true, foreign companies will more likely transact with Chinese companies to divest their product portfolios or localize the production of their assets in China. The new DAL is silent on whether the MAH system will retrospectively benefit products approved under the current regulatory regime. We hope the upcoming Drug Registration Rules will provide more information about the regulatory approval pathways and the transfer of marketing authorizations and legacy regulatory approvals under the new DAL.

Footnotes

1 See Ropes & Gray Alert dated May 15, 2019 for more details.

2 Vaccines, blood products, anesthetics, psychotics, medical toxins, radioactive drugs, and precursor chemicals.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions